Colorectal cancer is the third among the most common cancers. Worldwide, nearly 1.25 million patients are diagnosed with and more than 600,000 patients die from colorectal cancer each year. At least 50% of patients develop metastases, and most of these patients have unresectable tumours. Standard treatment for these patients involves chemotherapy and monoclonal antibodies.
The aim of the study observational CORRELATE is to characterize safety of regorafenib use in routine clinical practice settings in patients with metastatic colorectal cancer.
Regorafenib is a novel oral multikinase inhibitor that inhibits tumor growth. It was approved by the FDA in 2012 for the treatment of previously treated metastatic colorectal cancer.
The Centre Hospitalier de Luxembourg is involved and CIEC-LIH is actively assisting and supporting physicians involved in this trial. The total number of patients is 3000 with approximately 5 patients in Luxembourg.
More information here: www.luxclin.lu/Studies/Details/?c=STP8270LFQ
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.